3,393 press releases indexed under healthcare.
The company behind the InTheZone supplement brand has transformed its firsthand experience into a technology platform that helps founders build purpose-driven supplement brands with access to FDA-registered, cGMP-aligned manufacturing. NutraVeri is now the centerpiece of Nitches' long-term growth strategy.
(PR-inside.com) Internal Testing Demonstrates Strong Technical Progress and Positions MDCE for Growth in AI-Powered Preventive Wellness MESA, AZ / ACCESS Newswire / July 16, 2026 / Following the positive internal testing results announced on June 26, 2026, Medical Care Technologies, Inc. (OTC PINK:MDCE) today outlined the structured six-phase process applied to train and optimize its proprietary AI vision models for the MDCE Melanoma Scan Beta platform. To learn more about MDCE and its diversified technology initiatives, visit the corporate website atwww.medicalcaretechnologies.com . By leveraging leading public benchmark datasets, the Company has executed a rigorous, methodical development cycle designed to deliver robust, high-performing AI capabilities. ..
Internal Testing Demonstrates Strong Technical Progress and Positions MDCE for Growth in AI-Powered Preventive Wellness
Growing Interest From Leading Academic Investigators and Biopharmaceutical Companies in NeuroOne's Drug Delivery Platform EDEN PRAIRIE, MINN. - July 16, 2026 ( NEWMEDIAWIRE ) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced a collaboration with Mayo Clinic supporting a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive and difficult-to-treat childhood brain cancers. The program is supported by a grant recently awarded by the Children's Cancer Research Fund (CCRF) to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
Pilot Combines Clinician Guided Phenotypes with IMO Health's Unique Terminology Identifiers to Help Clinicians Easily Identify Patients Most Likely to Benefit from Pivot Insulin Pump Therapy Advancing Towards Fourth Quarter Commercial Launch of Pivot Pump
FDA-cleared, non-invasive, drug-free technology now available to VA and federal healthcare providers, supported by education, demonstration, onboarding, and implementation resources for clinic-to-home use.
Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612 ).
STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the combination of both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in Europe.
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan